Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.
FDA Greenlights Soliris for Rare Autoimmune Disease
Anti-aquaporin-4 (AQP4) antibody, Approvals, Biomarkers, Central Nervous System, European Medicines Agency (EMA), FDA, FDA/Regulatory, Generalized Myasthenia Gravis (gMG), Hemolytic Uremic Syndrome, Immune System, Japanese Ministry of Health, Neuromyelitis Optica Spectrum Disorder (NMOSD), New Indications, Paralysis, Paroxysmal Nocturnal Hemoglobinuria (PNH), Vision problemsThe U.S. FDA gave Alexion Pharmaceuticals a thumbs-up for Soliris (eculizumab) to treat neuromyelitis optica spectrum disorder in adults that express a specific biomarker.